Bayer sells Starck for €1.2bn

Gibson, Jane
November 2006
ICIS Chemical Business;11/27/2006, Vol. 1 Issue 45, p4
Trade Publication
This article reports that Bayer has agreed to sell its rare metals and electronic chemicals business HC Starck to private equity companies Advent International and The Carlyle Group. The proceeds will help finance Bayer's acquisition of drugs group Schering. Advent and Carlyle will pay €700 million in cash and assume financial liabilities and staff-related commitments of €450 million. The deal reduces Bayer's net debt by €1 billion, with an accounting gain of €150 million.


Related Articles

  • Bayer agrees to sell H.C. Starck for €1.2bn. Davis, Nigel // ICIS Chemical Business Americas;12/4/2006, Vol. 270 Issue 20, p4 

    The article reports on the sale of metals and powders company H.C. Starck by Bayer to private equity firms Advent International and the Carlyle Group. The amount paid by the private equity firms for Starck is disclosed. It also discloses the benefits derived by Bayer from the sale. A brief...

  • BRIEFS.  // Advanced Materials & Processes;Apr2007, Vol. 165 Issue 4, p13 

    This article offers news briefs in the field of material technology. A new web site is being launched by the Advanced Materials, Manufacturing and Testing Information Analysis Center. BASF Future Business GmbH will start production and sales of organic semiconductors this year. The Bayer Group...

  • KBE welcomes change of ownership.  // Glass Age;Apr2005, Vol. 48 Issue 4, p4 

    Reports on the transfer of ownership of HT Troplast AG to private equity firms Carlyle Group and Advent International Corp. Management changes at HT Troplast following the transfer; Effect of the move on the operations of subsidiary KBE.

  • Bayer to sell Rhein Chemie to equity group. Raleigh, Patrick // European Rubber Journal;Nov2002, Vol. 184 Issue 11, p3 

    Reports on the sale of the Rhein Chemie Rheinau GmbH subsidiary of Bayer AG to Advent International Corp. Value of the acquisition; Products of Rhein Chemie; Work force of Rhein.

  • Bayer's Sale of Rhein Chemie to Advent Falls Through.  // Chemical Week;12/11/2002, Vol. 164 Issue 48, p8 

    Reports on the sale of Manheim, Germany-based rubber chemicals and additive manufacturer Rhein Chemie by Bayer to Boston, Massachusetts-based private equity capital company Advent International. Value of the acquisition; Terms of the acquisition deal; Background on an investigation on Rhein...

  • LP Study: Assessing Strategy Drift. Davis, Avram; MacFadyen, Ken // Mergers & Acquisitions: The Dealermaker's Journal;Aug2008, Vol. 43 Issue 8, p30 

    The article discusses the trend of bigger firms making investments in distressed debt. In April 2008, Apollo Management, TPG Capital and Blackstone Group paid $12 billion for a mass of Citibank's leveraged loans and bonds. During the same month, Carlyle Group closed a $1.35 billion distressed...

  • Edscha will slash work force, close plants. Hamprecht, Harald // Automotive News;8/29/2005, Vol. 80 Issue 6163, p22F 

    This article focuses on the financial crisis faced by Edscha AG. Edscha raised its debt level last spring to give equity shareholder Carlyle Group Inc. a loan of more than $73 million at current exchange rates. But Edscha had difficulty meeting its debt obligations for June 2005. So management...

  • Ortho-Clinical Diagnostics, Inc.  // Distressed Company Alert;2/5/2016, Vol. 14 Issue 5, p23 

    The article offers information on the corporate performance of Ortho-Clinical Diagnostics Inc. Topics discussed include the impact of the company's higher leverage to the downgrade of its corporate family ratings, the sale of the company by pharmaceutical company Johnson & Johnson to financial...

  • Europe Watch.  // ICIS Chemical Business;2/12/2007, Vol. 2 Issue 53, p12 

    The article offers news briefs on the chemical industry in Europe. Zaklady Azotowe Pulawy is looking for acquisitions in Poland, as well as other central and eastern European countries. British Petroleum's refining and marketing business returned to profit in the fourth quarter of 2006. Bayer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics